Positive phase 3 results in breast cancer for Daiichi Sankyo , AstraZeneca datopotamab deruxtecan

 Plans for global regulatory submissions are underway

https://www.biospace.com/article/releases/datopotamab-deruxtecan-demonstrated-statistically-significant-and-clinically-meaningful-progression-free-survival-benefit-in-patients-with-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-3-trial/